Historical source coverage

2023

207 selected records with a cited source date in 2023, shown 200 per page, newest first. This archive is selective and does not imply continuous monitoring or complete historical coverage.

Explore 2023 by record type

4 types

December 2023

13 records on this page

Literature metadata · Pegcetacoplan

Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration.

PubMed lists PMID 38098608 in Annals of medicine and surgery (2012) as Journal Article, Review, with publication-date metadata of 2023-11-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Cerebrolysin

ClinicalTrials.gov record NCT00868283

PeptideScanner retained ClinicalTrials.gov record NCT00868283 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-12-15, and PeptideScanner's reviewed identity mapping was cerebrolysin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Dasiglucagon

ClinicalTrials.gov record NCT03777176

PeptideScanner retained ClinicalTrials.gov record NCT03777176 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-12-13, and PeptideScanner's reviewed identity mapping was dasiglucagon.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Etelcalcetide

Real-World Experience of Using Etelcalcetide for Secondary Hyperparathyroidism in Community-Based Hemodialysis Centers in Singapore.

PubMed lists PMID 38050530 in Cureus as Journal Article, with publication-date metadata of 2023-11-02 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT03795701

PeptideScanner retained ClinicalTrials.gov record NCT03795701 at 2026-07-30T19:03:45.488Z. Its registry update date was 2023-12-04, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Trofinetide

Trofinetide-a new chapter in rett syndrome's treatment.

PubMed lists PMID 38035006 in Frontiers in pharmacology as Journal Article, with publication-date metadata of 2023-11-16 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

November 2023

32 records on this page

Regulatory · Dasiglucagon

Federal Register notice 2023-26260

The Federal Register published notice 2023-26260, attributed to FDA and its parent HHS department, on 2023-11-30. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; ZEGALOGUE,” and PeptideScanner's exact reviewed identity mapping connects the document to Dasiglucagon.

Source: Federal Register via GovInfo ↗

→

Regulatory · Pegcetacoplan

Federal Register notice 2023-26255

The Federal Register published notice 2023-26255, attributed to FDA and its parent HHS department, on 2023-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Empaveli,” and PeptideScanner's exact reviewed identity mapping connects the document to Pegcetacoplan.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Teduglutide

ClinicalTrials.gov record NCT04290429

PeptideScanner retained ClinicalTrials.gov record NCT04290429 at 2026-11-15T21:55:23.600Z. Its registry update date was 2023-11-29, and PeptideScanner's reviewed identity mapping was teduglutide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Difelikefalin

Federal Register notice 2023-26106

The Federal Register published notice 2023-26106, attributed to FDA and its parent HHS department, on 2023-11-28. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; Korsuva,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Aviptadil

Peptiligase, an enzyme for efficient chemo-enzymatic synthesis of aviptadil.

PubMed lists PMID 37774815 in International journal of biological macromolecules as Journal Article, with publication-date metadata of 2023-09-27 (day precision). PeptideScanner associated the retained record with the identity slug aviptadil. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT02381249

PeptideScanner retained ClinicalTrials.gov record NCT02381249 at 2026-07-30T19:04:52.219Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Octreotide

ClinicalTrials.gov record NCT02385617

PeptideScanner retained ClinicalTrials.gov record NCT02385617 at 2026-07-30T19:04:52.214Z. Its registry update date was 2023-11-27, and PeptideScanner's reviewed identity mapping was octreotide.

Source: ClinicalTrials.gov ↗

→

Regulatory · Semaglutide

Federal Register notice 2023-25485

The Federal Register published notice 2023-25485, attributed to FDA and its parent HHS department, on 2023-11-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT00541047

PeptideScanner retained ClinicalTrials.gov record NCT00541047 at 2026-07-30T19:04:52.204Z. Its registry update date was 2023-11-13, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Linaclotide

Pharmacotherapy patterns in patients with chronic idiopathic constipation beginning treatment with linaclotide or lubiprostone in the United States.

PubMed lists PMID 32863841 in Drugs in context as Journal Article, with publication-date metadata of 2020-08-12 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Afamelanotide

Advances in the management of erythropoietic protoporphyria - role of afamelanotide.

PubMed lists PMID 28003770 in The application of clinical genetics as Review, Journal Article, with publication-date metadata of 2016-12-12 (day precision). PeptideScanner associated the retained record with the identity slug afamelanotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Lutetium Lu 177 dotatate

Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®.

PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Etelcalcetide

A Prospective, Randomized Clinical Trial of Etelcalcetide in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism (the DUET Trial).

PubMed lists PMID 33305109 in Kidney international reports as Journal Article, with publication-date metadata of 2020-09-18 (day precision). PeptideScanner associated the retained record with the identity slug etelcalcetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Desmopressin

Desmopressin in combination with anticholinergic agents in the treatment of nocturnal enuresis: a systematic review and meta-analysis.

PubMed lists PMID 37928358 in Frontiers in pediatrics as Journal Article, Review, with publication-date metadata of 2023-10-19 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Bivalirudin

Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials.

PubMed lists PMID 37746717 in Circulation as Meta-Analysis, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-09-25 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pasireotide

Pasireotide for Refractory Hypoglycemia in Malignant Insulinoma- Case Report and Review of the Literature.

PubMed lists PMID 35518928 in Frontiers in endocrinology as Case Reports, Review, Journal Article, with publication-date metadata of 2022-04-19 (day precision). PeptideScanner associated the retained record with the identity slug pasireotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Daptomycin

Federal Register notice 2023-24120

The Federal Register published notice 2023-24120, attributed to FDA and its parent HHS department, on 2023-11-01. Its official title is “Determination That CALCIUM DISODIUM VERSENATE (Edetate Calcium Disodium) Injection, 200 Milligrams per Milliliter, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

October 2023

15 records on this page

Literature metadata · GHK-Cu

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application.

PubMed lists PMID 37896245 in Pharmaceutics as Journal Article, with publication-date metadata of 2023-10-18 (day precision). PeptideScanner associated the retained record with the identity slug ghk-cu. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Dalbavancin

A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.

PubMed lists PMID 37887193 in Antibiotics (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-09-28 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Pramlintide

ClinicalTrials.gov record NCT05199714

PeptideScanner retained ClinicalTrials.gov record NCT05199714 at 2026-07-30T19:07:27.301Z. Its registry update date was 2023-10-25, and PeptideScanner's reviewed identity mapping was pramlintide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Trofinetide

Trofinetide.

PubMed lists PMID 37279541 in American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists as Journal Article, with publication-date metadata of 2023-07-21 (day precision). PeptideScanner associated the retained record with the identity slug trofinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Goserelin

Erythema nodosum caused by goserelin acetate sustained-release: Case report and literature review.

PubMed lists PMID 37114900 in International journal of rheumatic diseases as Review, Case Reports, Journal Article, with publication-date metadata of 2023-04-28 (day precision). PeptideScanner associated the retained record with the identity slug goserelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Desmopressin

Systematic Review and Meta-analysis of Alarm versus Desmopressin Therapy for Pediatric Monosymptomatic Enuresis.

PubMed lists PMID 30425276 in Scientific reports as Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't, Systematic Review, with publication-date metadata of 2018-11-13 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

September 2023

22 records on this page

Literature metadata · Difelikefalin

Difelikefalin in Hemodialysis Patients with Pruritus.

PubMed lists PMID 32433845 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Difelikefalin

Difelikefalin in Hemodialysis Patients with Pruritus.

PubMed lists PMID 32433846 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Difelikefalin

Difelikefalin in Hemodialysis Patients with Pruritus.

PubMed lists PMID 32433847 in The New England journal of medicine as Letter, Comment, with publication-date metadata of 2020-05-21 (day precision). PeptideScanner associated the retained record with the identity slug difelikefalin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Linaclotide

UK clinical experience up to 52 weeks with linaclotide for irritable bowel syndrome with constipation.

PubMed lists PMID 30302125 in Therapeutic advances in gastroenterology as Journal Article, with publication-date metadata of 2018-10-03 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Afamelanotide

ClinicalTrials.gov record NCT04525157

PeptideScanner retained ClinicalTrials.gov record NCT04525157 at 2026-07-30T19:08:50.172Z. Its registry update date was 2023-09-22, and PeptideScanner's reviewed identity mapping was afamelanotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Etelcalcetide

ClinicalTrials.gov record NCT03960437

PeptideScanner retained ClinicalTrials.gov record NCT03960437 at 2026-11-15T22:07:29.454Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was etelcalcetide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Setmelanotide

ClinicalTrials.gov record NCT02896192

PeptideScanner retained ClinicalTrials.gov record NCT02896192 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-21, and PeptideScanner's reviewed identity mapping was setmelanotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Zilucoplan

ClinicalTrials.gov record NCT04382755

PeptideScanner retained ClinicalTrials.gov record NCT04382755 at 2026-11-15T21:46:36.651Z. Its registry update date was 2023-09-14, and PeptideScanner's reviewed identity mapping was zilucoplan.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Desmopressin

Comparative Analysis of Solifenacin Plus Desmopressin Versus Desmopressin Alone in the Treatment of Primary Mono Symptomatic Nocturnal Enuresis.

PubMed lists PMID 37041092 in Journal of pediatric surgery as Randomized Controlled Trial, Journal Article, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Motixafortide

Drugs@FDA application NDA217159

The official Drugs@FDA dataset lists original submission 1 for NDA 217159 with status AP dated 2023-09-08, and names motixafortide acetate among the application record's active ingredients.

Source: Drugs@FDA via openFDA ↗

→

Clinical trials · Semaglutide

ClinicalTrials.gov record NCT04263415

PeptideScanner retained ClinicalTrials.gov record NCT04263415 at 2026-07-30T19:08:50.175Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was semaglutide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Liraglutide

ClinicalTrials.gov record NCT03737240

PeptideScanner retained ClinicalTrials.gov record NCT03737240 at 2026-07-30T19:08:50.174Z. Its registry update date was 2023-09-08, and PeptideScanner's reviewed identity mapping was liraglutide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Bivalirudin

Is it time to switch to bivalirudin for ECMO anticoagulation?

PubMed lists PMID 37671395 in Frontiers in medicine as Journal Article, Review, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Bivalirudin

Federal Register notice 2023-19013

The Federal Register published notice 2023-19013, attributed to FDA and its parent HHS department, on 2023-09-05. Its official title is “Merck Sharp & Dohme LLC, et al.; Withdrawal of Approval of 35 New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Bivalirudin.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Linaclotide

Linaclotide (Linzess) for functional constipation.

PubMed lists PMID 37651297 in The Medical letter on drugs and therapeutics as Journal Article, with publication-date metadata of 2023-08-21 (day precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Gallium Ga 68 dotatate

ClinicalTrials.gov record NCT03953131

PeptideScanner retained ClinicalTrials.gov record NCT03953131 at 2026-11-16T17:36:42.191Z. Its registry update date was 2023-09-01, and PeptideScanner's reviewed identity mapping was gallium-ga-68-dotatate.

Source: ClinicalTrials.gov ↗

→

August 2023

14 records on this page

Literature metadata · Teduglutide

Expression, Purification and Characterization of Functional Teduglutide Using GST Fusion System in Prokaryotic Cells.

PubMed lists PMID 37646058 in Advanced pharmaceutical bulletin as Journal Article, with publication-date metadata of 2022-12-06 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Exenatide

Federal Register notice 2023-18241

The Federal Register published notice 2023-18241, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Alternative Form of Hearing,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

Regulatory · Exenatide

Federal Register notice 2023-18250

The Federal Register published notice 2023-18250, attributed to FDA and its parent HHS department, on 2023-08-24. Its official title is “Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide.

Source: Federal Register via GovInfo ↗

→

Regulatory · Glucagon + 1 more

Federal Register notice 2023-18026

The Federal Register published notice 2023-18026, attributed to FDA and its parent HHS department, on 2023-08-22. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Glucagon and Tirzepatide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Cerebrolysin

Noninvasive monitoring in a patient with SAH diagnosis treated with Cerebrolysin - case report and review of the literature.

PubMed lists PMID 37522695 in European review for medical and pharmacological sciences as Review, Case Reports, Journal Article, with publication-date metadata of 2023-07 (month precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Elamipretide

Use of Elamipretide in patients assigned treatment in the compassionate use program: Case series in pediatric patients with rare orphan diseases.

PubMed lists PMID 36636586 in JIMD reports as Journal Article, with publication-date metadata of 2022-09-21 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Daptomycin

Federal Register notice 2023-16775

The Federal Register published notice 2023-16775, attributed to FDA and its parent HHS department, on 2023-08-07. Its official title is “Determination That CUBICIN (Daptomycin) Powder for Injection, 250 Milligrams/Vial and 500 Milligrams/Vial, and CUBICIN RF (Daptomycin) Powder for Injection, 500 Milligrams/Vial, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Daptomycin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Desmopressin

ClinicalTrials.gov record NCT03389412

PeptideScanner retained ClinicalTrials.gov record NCT03389412 at 2026-11-16T01:33:21.554Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was desmopressin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT04026256

PeptideScanner retained ClinicalTrials.gov record NCT04026256 at 2026-07-30T19:09:38.366Z. Its registry update date was 2023-08-02, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Dalbavancin

Dalbavancin in Bone and Joint Infections: A Systematic Review.

PubMed lists PMID 37513919 in Pharmaceuticals (Basel, Switzerland) as Journal Article, Review, with publication-date metadata of 2023-07-15 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

July 2023

16 records on this page

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT04879420

PeptideScanner retained ClinicalTrials.gov record NCT04879420 at 2026-07-30T19:10:42.715Z. Its registry update date was 2023-07-27, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Degarelix

Investigation of the GnRH antagonist degarelix isomerization in biological matrices.

PubMed lists PMID 37455491 in Pharmacology research & perspectives as Journal Article, with publication-date metadata of 2023-08 (month precision). PeptideScanner associated the retained record with the identity slug degarelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pegcetacoplan

Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

PubMed lists PMID 37195551 in PharmacoEconomics - open as Journal Article, Review, with publication-date metadata of 2023-05-17 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Pegcetacoplan

ClinicalTrials.gov record NCT03525613

PeptideScanner retained ClinicalTrials.gov record NCT03525613 at 2026-11-16T01:37:14.654Z. Its registry update date was 2023-07-06, and PeptideScanner's reviewed identity mapping was pegcetacoplan.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Enfuvirtide

Development of a HPLC fluorometric method for the quantification of enfuvirtide following in vitro releasing studies on thermosensitive in situ forming gel.

PubMed lists PMID 37120679 in Drug delivery and translational research as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-04-29 (day precision). PeptideScanner associated the retained record with the identity slug enfuvirtide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

June 2023

16 records on this page

Literature metadata · Teduglutide

Teduglutide for the treatment of short bowel syndrome: a double-edged sword?

PubMed lists PMID 37270286 in The American journal of clinical nutrition as Editorial, Comment, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Teduglutide

Long-term treatment with teduglutide: a 48-week open-label single-center clinical trial in children with short bowel syndrome.

PubMed lists PMID 37270289 in The American journal of clinical nutrition as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-05-03 (day precision). PeptideScanner associated the retained record with the identity slug teduglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · MOTS-c

Mitochondrial-Encoded Peptide MOTS-c, Diabetes, and Aging-Related Diseases.

PubMed lists PMID 36824008 in Diabetes & metabolism journal as Journal Article, Review, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, with publication-date metadata of 2023-02-24 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Pegcetacoplan

WITHDRAWN: Pegcetacoplan in the treatment of geographic atrophy.

PubMed lists PMID 37259853 in Immunotherapy as Journal Article, Review, with publication-date metadata of 2023-06-01 (day precision). PeptideScanner associated the retained record with the identity slug pegcetacoplan. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

May 2023

19 records on this page

Clinical trials · Setmelanotide

ClinicalTrials.gov record NCT03287960

PeptideScanner retained ClinicalTrials.gov record NCT03287960 at 2026-07-30T19:13:03.752Z. Its registry update date was 2023-05-23, and PeptideScanner's reviewed identity mapping was setmelanotide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Lixisenatide

Comprehensive Evaluation of Combination Therapy with Basal Insulin and Either Lixisenatide or Vildagliptin in Japanese Patients with Type 2 Diabetes: A Randomized, Open-Label, Parallel-Group, Multice…

PubMed lists PMID 30206903 in Diabetes therapy : research, treatment and education of diabetes and related disorders as Journal Article, with publication-date metadata of 2018-09-11 (day precision). PeptideScanner associated the retained record with the identity slug lixisenatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Difelikefalin

Federal Register notice 2023-10710

The Federal Register published notice 2023-10710, attributed to FDA and its parent HHS department, on 2023-05-19. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Difelikefalin.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Daptomycin

Daptomycin for the treatment of acute bacterial meningitis: A narrative review.

PubMed lists PMID 36870402 in International journal of antimicrobial agents as Journal Article, Review, with publication-date metadata of 2023-03-02 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Lutetium Lu 177 dotatate

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.

PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

April 2023

11 records on this page

Literature metadata · Bivalirudin

Comparison of Bivalirudin Versus Heparin for Anticoagulation During Extracorporeal Membrane Oxygenation.

PubMed lists PMID 36194483 in ASAIO journal (American Society for Artificial Internal Organs : 1992) as Systematic Review, Meta-Analysis, Journal Article, with publication-date metadata of 2022-04-10 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Cerebrolysin

ClinicalTrials.gov record NCT05807503

PeptideScanner retained ClinicalTrials.gov record NCT05807503 at 2026-11-16T17:33:14.861Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was cerebrolysin.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Metreleptin

Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.

PubMed lists PMID 25070319 in The Journal of clinical endocrinology and metabolism as Controlled Clinical Trial, Journal Article, Research Support, N.I.H., Intramural, with publication-date metadata of 2014-07-29 (day precision). PeptideScanner associated the retained record with the identity slug metreleptin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Afamelanotide

ClinicalTrials.gov record NCT04962503

PeptideScanner retained ClinicalTrials.gov record NCT04962503 at 2026-07-30T19:14:02.188Z. Its registry update date was 2023-04-11, and PeptideScanner's reviewed identity mapping was afamelanotide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Thymosin alpha-1

ClinicalTrials.gov record NCT02867267

PeptideScanner retained ClinicalTrials.gov record NCT02867267 at 2026-11-15T22:10:40.222Z. Its registry update date was 2023-04-10, and PeptideScanner's reviewed identity mapping was thymosin-alpha-1.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Abaloparatide

ClinicalTrials.gov record NCT03512262

PeptideScanner retained ClinicalTrials.gov record NCT03512262 at 2026-07-30T19:14:02.186Z. Its registry update date was 2023-04-07, and PeptideScanner's reviewed identity mapping was abaloparatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Terlipressin

ClinicalTrials.gov record NCT04416282

PeptideScanner retained ClinicalTrials.gov record NCT04416282 at 2026-11-15T21:47:40.408Z. Its registry update date was 2023-04-06, and PeptideScanner's reviewed identity mapping was terlipressin.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Bivalirudin

Heparin-based versus bivalirudin-based anticoagulation in pediatric extracorporeal membrane oxygenation: A systematic review.

PubMed lists PMID 36999064 in Frontiers in medicine as Systematic Review, Journal Article, with publication-date metadata of 2023-03-14 (day precision). PeptideScanner associated the retained record with the identity slug bivalirudin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

March 2023

19 records on this page

Literature metadata · Gonadorelin

Advances and perspectives in the analytical technology for small peptide hormones analysis: A glimpse to gonadorelin.

PubMed lists PMID 36858006 in Journal of pharmaceutical and biomedical analysis as Case Reports, Journal Article, Review, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug gonadorelin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Cerebrolysin

Cerebrolysin in Patients with TBI: Systematic Review and Meta-Analysis.

PubMed lists PMID 36979317 in Brain sciences as Journal Article, Review, with publication-date metadata of 2023-03-17 (day precision). PeptideScanner associated the retained record with the identity slug cerebrolysin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Eptifibatide

Eptifibatide, an Older Therapeutic Peptide with New Indications: From Clinical Pharmacology to Everyday Clinical Practice.

PubMed lists PMID 36982519 in International journal of molecular sciences as Journal Article, Review, with publication-date metadata of 2023-03-13 (day precision). PeptideScanner associated the retained record with the identity slug eptifibatide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Trofinetide

Federal Register notice 2023-06593

The Federal Register published notice 2023-06593, attributed to FDA and its parent HHS department, on 2023-03-30. Its official title is “Issuance of Priority Review Voucher; Rare Pediatric Disease Product,” and PeptideScanner's exact reviewed identity mapping connects the document to Trofinetide.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Dalbavancin

Global trends of dalbavancin: A bibliometric analysis.

PubMed lists PMID 35735062 in Journal of clinical pharmacy and therapeutics as Journal Article, Review, with publication-date metadata of 2022-06-23 (day precision). PeptideScanner associated the retained record with the identity slug dalbavancin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Motixafortide

Structural Basis of the Binding Mode of the Antineoplastic Compound Motixafortide (BL-8040) in the CXCR4 Chemokine Receptor.

PubMed lists PMID 36901829 in International journal of molecular sciences as Journal Article, with publication-date metadata of 2023-02-23 (day precision). PeptideScanner associated the retained record with the identity slug motixafortide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Icatibant

Federal Register notice 2023-04175

The Federal Register published notice 2023-04175, attributed to FDA and its parent HHS department, on 2023-03-01. Its official title is “Mylan Pharmaceuticals Inc., et.al.; Withdrawal of Approval of 11 Abbreviated New Drug Applications,” and PeptideScanner's exact reviewed identity mapping connects the document to Icatibant.

Source: Federal Register via GovInfo ↗

→

February 2023

20 records on this page

Literature metadata · MOTS-c

Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study.

PubMed lists PMID 36844198 in Frontiers in medicine as Journal Article, with publication-date metadata of 2023-02-08 (day precision). PeptideScanner associated the retained record with the identity slug mots-c. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Literature metadata · Linaclotide

Editorial: repurposed linaclotide and the quest for abdominal pain management in irritable bowel syndrome.

PubMed lists PMID 36565004 in Alimentary pharmacology & therapeutics as Editorial, Comment, with publication-date metadata of 2023-01 (month precision). PeptideScanner associated the retained record with the identity slug linaclotide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Dasiglucagon

ClinicalTrials.gov record NCT03895697

PeptideScanner retained ClinicalTrials.gov record NCT03895697 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-21, and PeptideScanner's reviewed identity mapping was dasiglucagon.

Source: ClinicalTrials.gov ↗

→

Regulatory · Calcitonin salmon

Federal Register notice 2023-03389

The Federal Register published notice 2023-03389, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Determination That MIACALCIN (Calcitonin Salmon) Injection, 100 USP Units/Milliliter (mL), Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Calcitonin salmon.

Source: Federal Register via GovInfo ↗

→

Literature metadata · Daptomycin

Bacterial cell membranes and their role in daptomycin resistance: A review.

PubMed lists PMID 36452455 in Frontiers in molecular biosciences as Journal Article, Review, with publication-date metadata of 2022-11-14 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Afamelanotide + 3 more

Federal Register notice 2023-03364

The Federal Register published notice 2023-03364, attributed to FDA and its parent HHS department, on 2023-02-17. Its official title is “Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,” and PeptideScanner's exact reviewed identity mapping connects the document to Afamelanotide, Glucagon, Leuprolide and Vosoritide.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Leuprolide

ClinicalTrials.gov record NCT03043807

PeptideScanner retained ClinicalTrials.gov record NCT03043807 at 2026-07-30T19:16:22.177Z. Its registry update date was 2023-02-16, and PeptideScanner's reviewed identity mapping was leuprolide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Abaloparatide

ClinicalTrials.gov record NCT04064411

PeptideScanner retained ClinicalTrials.gov record NCT04064411 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-15, and PeptideScanner's reviewed identity mapping was abaloparatide.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT04589819

PeptideScanner retained ClinicalTrials.gov record NCT04589819 at 2026-07-30T19:16:22.171Z. Its registry update date was 2023-02-13, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Desmopressin

Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.

PubMed lists PMID 35839450 in Blood as Journal Article, Randomized Controlled Trial, with publication-date metadata of 2022-09-08 (day precision). PeptideScanner associated the retained record with the identity slug desmopressin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Clinical trials · Afamelanotide

ClinicalTrials.gov record NCT05368857

PeptideScanner retained ClinicalTrials.gov record NCT05368857 at 2026-07-30T19:16:22.169Z. Its registry update date was 2023-02-09, and PeptideScanner's reviewed identity mapping was afamelanotide.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Daptomycin

Daptomycin synergistic properties from in vitro and in vivo studies: a systematic review.

PubMed lists PMID 36227704 in The Journal of antimicrobial chemotherapy as Systematic Review, Journal Article, with publication-date metadata of 2022-12-23 (day precision). PeptideScanner associated the retained record with the identity slug daptomycin. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

Regulatory · Desmopressin

Federal Register notice 2023-02442

The Federal Register published notice 2023-02442, attributed to FDA and its parent HHS department, on 2023-02-06. Its official title is “Determination That TRIAMCINOLONE ACETONIDE (Triamcinolone Acetonide) Topical Cream, 0.025% and 0.1%, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness,” and PeptideScanner's exact reviewed identity mapping connects the document to Desmopressin.

Source: Federal Register via GovInfo ↗

→

Clinical trials · Dasiglucagon

ClinicalTrials.gov record NCT04836273

PeptideScanner retained ClinicalTrials.gov record NCT04836273 at 2026-11-16T01:42:39.027Z. Its registry update date was 2023-02-02, and PeptideScanner's reviewed identity mapping was dasiglucagon.

Source: ClinicalTrials.gov ↗

→

Literature metadata · Pramlintide

Development and validation of a new robust RP-HPLC method for simultaneous quantitation of insulin and pramlintide in non-invasive and smart glucose-responsive microparticles.

PubMed lists PMID 36704426 in Research in pharmaceutical sciences as Journal Article, with publication-date metadata of 2022-10-29 (day precision). PeptideScanner associated the retained record with the identity slug pramlintide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

Source: PubMed ↗

→

January 2023

3 records on this page

Clinical trials · Bivalirudin

ClinicalTrials.gov record NCT03318393

PeptideScanner retained ClinicalTrials.gov record NCT03318393 at 2026-11-15T21:58:19.888Z. Its registry update date was 2023-01-31, and PeptideScanner's reviewed identity mapping was bivalirudin.

Source: ClinicalTrials.gov ↗

→

Clinical trials · Teriparatide

ClinicalTrials.gov record NCT03472846

PeptideScanner retained ClinicalTrials.gov record NCT03472846 at 2026-07-30T19:17:35.707Z. Its registry update date was 2023-01-26, and PeptideScanner's reviewed identity mapping was teriparatide.

Source: ClinicalTrials.gov ↗

→